EASD 2025 15 - 19 September 2025

CagriSema improves glycaemic outcomes across weight loss categories in adults with BMI ≥27 kg/m² and type 2 diabetes (T2D) within the blinded continuous glucose monitoring (CGM) subgroup in REDEFINE 2

Authors :

Richard Pratley¹; Harpreet S. Bajaj²; Christa Broholm³; Maria M Byrne⁴; Mikkel Hovden Christensen³; Astrid Eliasen³; Josefine Nadia Kraft³; Ildiko Lingvay⁵; Sean Wharton⁶; Melanie J. Davies²

Affiliations

View Details Hide Details

Keywords

Obesity

Congress oral presentation

GLP-1 RA

CagriSema

PHASE 3 (RCT)

Search Science Hub

Are you a healthcare professional?

CagriSema improves glycaemic outcomes across weight loss categories in adults with BMI ≥27 kg/m² and type 2 diabetes (T2D) within the blinded continuous glucose monitoring (CGM) subgroup in REDEFINE 2

Search Science Hub

Are you a healthcare professional?

CagriSema improves glycaemic outcomes across weight loss categories in adults with BMI ≥27 kg/m2 and type 2 diabetes (T2D) within the blinded continuous glucose monitoring (CGM) subgroup in REDEFINE 2

CagriSema improves glycaemic outcomes across weight loss categories in adults with BMI ≥27 kg/m² and type 2 diabetes (T2D) within the blinded continuous glucose monitoring (CGM) subgroup in REDEFINE 2